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CHAPTER ONE: INTRODUCTION 
COLORECTAL CARCINOMA IN SOUTH AFRICA 
3 
Worldwide, 875 000 new colorectal carcinoma cases, estimated in 1996, 
representing 8.5% of all newly diagnosed carcinomas are believed to occur [1]. 
Most ofthese are considered sporadic (80%). 10-15% are known familial risk and 
5-10% are genetic inherited [2]. These subsets of inherited cancer syndromes 
are well studied in an attempt to understand the carcinogenesis of colorectal 
carcinoma and ultimately the prevention and treatment thereof. 
A great variation of incidence around the world IS seen with developed countries 
such as North and South America, Europe, Australia, New Zealand and part of 
Asia with still low but rising rates in Malaysia and Korea and relative low 
incidence in Africa and Asia. Significant differences are also noted within the 
same countries [3]. 
Immigrants and their descendants who have relocated from low incidence 
countries to high incidence countries rapidly reach the incidence rates of the high 
incidence countries, indicating the importance of environmental factors. The 
incidence in Korea, Japan and Singapore has rapidly increased probably related 
to their adopted western life style [4]. 
An increasing incidence of colorectal carcinoma is noted not only in African 


















The etiology of colorectal carcinoma is multifactorial with both environmental 
(local toxic effects and mutation) and constitutional factors (e.g. germline· 
mutation of repair gene) playing a role in development and progression of 
colorectal carcinoma [7, 8]. Many studies on dietary and environmental factors 
were performed. The difficUlty in interpreting these results is multiple variables 
and inconsistent findings in different populations and circumstances of 
individuals. Dietary factors such as animal fat, refined carbohydrates, low fiber 
diet, lack of vegetables and trace elements are potential risk factors for 
carcinogenesis [9-14]. Epidemiological studies indicate that meat consumption, 
smoking and alcohol are risk factors whereas a vegetable rich diet, prolonged 
use of non-steroidal anti-inflammatory drugs, oestrogen replacement therapy and 
physical activity are protective [1, 15]. Some studies suggest carcinogens 
produced by bacteria. Others postulate the carcinogenic role of bile acids [16-19]. 
All these factors certainly may playa role in initiation or progression of carcinoma 
together with interaction between environment and gene mutation. 
Chronic inflammatory conditions of the colon are associated with an increased 
risk to develop carcinoma (eight to ten fold in longstanding pancolitis in ulcerative 
colitis) [20]. I n ulcerative colitis the risk of developing carcinoma is directly related 
to the extent of involvement. If more than half the colon affected, the risk of 
developing carcinoma is 15%. If only the left colon affected, the risk is 5% and 











disease the risk is reported to be three-fold [27J. Radiation is a known etiological 
factor with patients at increased risk after therapeutic irradiation [28]. Patients 
with ulcerative colitis and primary sclerozing cholangitis who undergo liver 
transplantation are also at increased risk for developing colorectal .carcinoma 
[29J. 
Several studies on the South African population have been conducted since an 
interesting mixture of Western descendants, African descendants and African 
descendents with westernized diets are represented within the Southern African 
population group. 
The incidence of malignancies of the gastrointestinal tract in patients in Groote 
Schuur Hospital, Cape Town [30] were as follows in decreasing order: 
1. stomach (29.6%), 
2. colon and rectum (29.5%) and 
3. oesophageal carcinoma (19.8%). 
Marked differences in the site of the carcinoma according to race were found; 
oesophageal carcinoma was the most frequent in black South African patients 
(62.1 %), gastriC carcinoma in colored (44.1 %) and colorectal carcinoma in wh ite 
patients (46.8%). Black African patients rarely showed pancreatic (5.1 %) or 














Poorly differentiated signet and mucinous type adenocarcinoma of the 
colo rectum have often been noted in very young black South· African patients 
(often younger than 25 years of age) showing very aggressive behavior and poor 
prognosis. No pre-malignant lesions could be identified in these case reports. 
Several such case reports and small series were published [31]. 
Two studies done in South Africa show contrasting results: one showing an 
increase in incidence of colorectal carcinoma in black South African patients [31]. 
Two periods were evaluated: the one being 1986-87 and the second 1996-97. 
Also an increase of adenomatous polyps were noted and a younger age of onset 
(less than 40 years old) was noted [32}. 
In contrast to the above study a second study showing a still low incidence with 
occasional associated adenomatous polyps (5.2%) in patients with westernized 
diets (1991 and 1996).6% occurred in patients younger than 30 years of age and 
22% before the age of 40. More than three quarters arose in sigmoid and rectum 
with none arising in the right colon with nearly a third of cases were mucinous or 
signet ring cell carcinoma type [33). Large bowel carcinomas in black South 
African patients show a very high percentage (31%) of high grade mucinous and 












Another study shows a high proportion of cases with early onset (32.4% are 
younger than 40 years old) of which a very high proportion (45%) were right 
sided neoplasia [35]. 
Dietary factors were extensively studied in black South Africa with multiple 
variables and inconclusive results [36]. 
Another interesting finding in African patients is the low number of adenomatous 
polyps, synchronous carcinomas and diverticular disease [37]. 
1. HEREDITARY NON-POLYPOSIS COLORECTAL CARCINOMA (HNPCC) 
Inherited cancer syndromes involving the colon include familial adenomatous 
polyposis (FAP), juvenile polyposis and hereditary non-polyposis colorectal 
carcinoma (HNPCC). 
HNPCC (also known as Lynch syndrome or hereditary mismatch repair 
deficiency syndrome or HMRDS) is inherited in an autosomal dominant fashion 
and was originally recognized by Warthin and described by Lynch [38-42]. Today 
we know at least six mismatch repair genes involved in HNPCC. These have 












Clinical features of individuals with HNPCC include a high risk of developing· 
colorectal carcinoma (70-85%) and endometrial carcinomas (50%) often at an 
early age (mean of 45 years old) [43, 44J. The colonic carcinomas are located in 
the proximal (right sided) colon in more than 65% of cases. Metachronous and 
synchronous carcinomas are seen in up to 35% of patients often presenting with 
multiple lesions (but not hundreds as seen in FAP). Therefore the name non-
polyposis is used, although polyps are strictly speaking present. 
At clinical presentation, the patients are less likely to have lymph node 
involvement or metastases even if the individuals picked up on screening 
(surveillance) programs are excluded [45]. 
Extracolonic neoplasias described include endometrial, ovary, breast, renal 
pelvis. ureter, stomach. pancreas and small bowel [40. 41,46,47]. 
Glioblastoma associated with colorectal adenomas/carcinomas is referred to as 
Turcot syndrome where as sebaceous gland adenomas/carcinomas with 
colorectal carcinomas is referred to as Muir-Torre syndrome. Both show some· 















The macroscopic features of colonic adenocarcinomas in HNPCC are in most 
cases similar to those seen in non-familial carcinomas with a high frequency of 
microsatellite instability (MSI-H). 
Macroscopical characteristics include a predilection for the proximal (right sided) 
colon [45}. This includes the caecum and ascending colon [41}. 
The lesions are mostly polypoid, well circumscribed, with ulcers, plaques and 
seldom show a diffuse infiltrating pattern [52, 53]. Therefore these patients often 
present only late in disease progression with bowel obstruction. 
Adenomas are present but less numerous than in FAP and more prevalent as in 
age matched controls of the general population [54]. Adenomas are not 
predominantly present in the right colon in older individual due to development of 
sporadic adenomas in the distal colon in this age group [54]. The relative low 
numbers of adenomas is thought to be as a result of the rapid accumulation of 
genetic alterations and therefore rapid progression from normal vulnerable 
epithelium (microscopically normal) through adenomas With dysplasia to 
infiltrating carcinoma [55]. This is also reflected in our own clinical survey (yearly) 
where individuals at risk had colonoscopies with no macroscopic abnormalities 
presenting with infiltrating colorectal carcinoma and multiple adenomas a year 
later reflecting very rapid progression in initial carcinogenesis (unpublished data, 













Tubulo-villous or villous adenomas are usually seen adjacentto infiltrating 
carcinomas. The adenomas more often show often high-grade epithelial 
dysplasia with rapid progression, as earlier described. Flat adenomas are usually 
only identified on histological examination showing a single crypt or few adjacent 
crypts with epithelial dysplasia. These then progress to polypoid adenomas. 
Microscopically HNPCC are said to show "typical" but not diagnostic features. 
These include mucinous carcinomas (more than 50% mucinous component by 
convention) with well circumscribed borders, poorly differentiated carcinomas 
(high grade), intratumoral lymphocyte infiltration, marked lymphocytic infiltration 
surrounding the tumour and lymphoid aggregates in the adjacent stroma ("Crohn-
like inflammation") (45, 52, 53, 56]. 
Individuals with MSH2 mutations more often show mucinous tumours and poorly 
differentiated carcinomas, whereas MLH1 mutations show more often the 
histological features of intratumorallymphocytes and Like-like inflammation [53]. 
Extracolonic cancers are more commonly seen in patients with MSH2 mutations 
compared to those with MLH1 mutations [57]. MSH6 mutations are associated 











1.1. MOLECULAR MECHANISM AND CARCINOGENESIS IN CRC 
The study of carcinogenesis and molecular mechanism in the field of colorectal 
carcinoma has been particularly fruitful in our understanding of carcinogenesis in 
general. This is mostly due to the intensive study of familial cancer syndromes 
such as F AP and HNPCC, which led to the discovery of important cancer genes. 
These genes play an important role. not only in familial cancers (colonic and 
extracolonic) but also play important roles in carcinogenesis of sporadic 
carcinomas, albeit at different stages in carcinogenesis [60]. 
The multistep carcinogenesis (adenoma-carcinoma sequence) concept is well 
described and accepted in sporadic carcinomas and supported by clinical, 
pathological and epidemiological data [61J. In the histological normal epithelium 
genetic alteration may already be . present. This might be either in the form of a 
germ line mutation or an acquired somatic mutation resulting in epithelium at risk. 
A second mutation resulting in the inactivation of the wild-type allele results in 
clonal proliferation of cells. Each step is initialized by a genetic change with 
clonal proliferation, different characteristics and biologicalbehavior [7, 62}. 
Two different pathways have been described for genetic changes in 
carcinogenesis: classic (or "gatekeeper") and alternative (or "caretaker") 
pathways. "Gatekeeper" genes are those initializing the first mutations and 
genetic alteration leading the epithelium into the first steps of carcinogenesis 











and NF-1 [7]. See figure 1.1 below of examples of inherited cancer genes and 
their loci. 
Fig 1.1: Examples of genes involved in inherited cancer syndromes. On this 
figure the gene name and its location is indicated next to the gene. Note gene 
number 2 (MSH2 and PMS1), gene 3 (MLH1) and gene 7 (PMS2) often mutated 
in HNPCC. 
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Contrasted to this, "caretaker" genes repair altered DNA and prevent small 
genetic alterations to proliferate and expand resulting in genomic instability. 











For carcinogenesis via this pathway, four steps are needed to enter clonal 
proliferation. A first somatic mutation of one allele of the caretaker gene, then a 
second hit to the other allele with inactivation of the caretaker gene. This per se 
is not enough to result in clonal expansion but does cause genomic instability. 
Both copies of gatekeeper genes (e.g. APC) need to be inactivated resulting in 
clonal expansion. In contrast, patients who already have one germline gene 
defect require only three more genetic alterations to enter carcinogenesis, 
therefore being at much higher risk to develop early and multiple carcinomas. 
In sporadic carcinomas the multistep carcinogenesis can be summarized as 
follows (see also table 1.1): 
APe mutation is most often the first alteration in at least 80% of sporadic 
colorectal carcinoma with less frequent mutations of mismatch repair genes. 
Early hypomethylation occurs resulting in activation of oncogenes. These include 
K-ras (chromosome 12p12), which plays a role in intracellular signal 
transduction. This gene is mutated in 50% percent of large adenomas and 
infiltrating carcinomas. 
DCC (deleted in colon cancer, a cell adhesion molecule, chromosome 18q21) is 
normally widely expressed in normal colonic epithelium and reduced in 70-75% 















P53 (chromosome 17p13) mutations in 70-80% in infiltrating carcinomas are 
seen and infrequently present in adenomas suggesting a late mutation [60]. 
In the progression from adenoma to carcinoma, subsequent late mutations and 
loss of heterozygosity occur with inactivation of the second allele (,second hit") in 
p53 and DCC genes [60]. 
Late changes associated with infiltrating carcinoma and progression includes 
multiple additional mutations and gross chromosomal alterations [60]. 
A few topical concepts in colorectal carcinogenesis are disclJssed below. 
1.1.1. Methylation 
Both hyper~ and hypomethylation of DNA occur in carcinogenesis of colorectal 
carcinoma although the exact cause is not fully understood. Methylation occurs 
at the CpG sites of genes. Genes rich in CpG sites are therefore prone to be 
silenced by methylation [63]. Two types of methylation (type A associated with 
ageing and in some colorectal carcinomas and type C associated only with 
carcinoma) have been described [64]. MLH~1 gene is one mismatch repair gene 
associated with methylation thus resulting in microsatellite instability in sporadic 















Methylguanine DNA methylatransferase (MGMT), also effected by methylation, 
and K-ras are linked to MSI-L pathway in which K-ras mutation is frequent [66, 
67]. Other genes inactivated by methylation include oestrogen receptor, HPP1, 
COX-2, p14 and p16 [63,68-721. 
1.1.2. Microsatellite instability 
Microsatellites are tandem repeats of either mononucleotide (AAAAA) or 
dinucleotide (ACACAC) base pairs in the non-coding regions of the genome. 
These changes often happen during replication and are particularly prone in 
tissue with high turnover of cells and constant replication. With normal repair 
genes, these "spelling errors" are repaired. If the repair mechanism is impaired, 
accumulation of satellites occurs resulting in an instable genome -the 
microsatellite instability. The grade of instability is measured by bandshifts in a 
panel of microsatellite markers. For high microsatellite instability {MSI-H}, at least 
40% of the markers should show a bandshift whereas less than 40% are 
considered microsatellite stable (MSS or MSI-L) [73}. 
Mixed hyperplastic polyps, serrated adenomas, adenomas and carcinomas in 
HNPCC interestingly show MSI-H contrasted to sporadic adenomas, which are 
MSS [74, 75]. MSI-H carcinomas show reduced mutation of APC. p53and K-ras 
and commonly show LOH at 5q, 17p and 18q [52,66,76-79]. Contrasted to this, 
mutations are commonly encountered in TGFRII, IGF2R, BAX, E2F-4, MSH3, 















DNA microsatellite instability is an important marker in identifying HNPCC 
carcinoma. A panel of five markers is recommended currently and includes 
BAT25, BAT26 , 02S123, 05S346 and 017S250 [73, 81]. About 60% of 
adenomas in patients with HNPCC are MSI-H [82]. MSI-H is seen in all HNPCC 
and in up to 30% (but in the range of 10-15% [73] of sporadic carcinomas, thus 
useful in identifying possible HNPCC cases. 
1.1.3. The hyperproliferation concept and flat adenomas 
Pioneering work by Upken and Deschner {86] on cell kinetic studies, evaluating 
the cell proliferation in normal colonic crypts and adenomas of FAP families, was 
done. Two phases were identified: phase 1: proliferation limited to cells of the 
lower compartment, phase 2: cycling cells in the upper and surface compartment 
progressing to adenomas [83, 84]. Several problems occur with this theory 
amongst others that anatomical site, gender, bowel preparation, age, diet, 
chronic diseases and other variables influence the changes noted [85-88]. Other 
changes noted are fission of crypts and decreased apoptosis in the upper crypt 
zones and surface epithelium, reversible by COX-2 inhibitors [89, 90]. 
Unicryptal adenomas start as a small bud from the side of a normal crypt, 
forming a tubule migrating to the surface of the luminal epithelium. Fission occurs 













few crypts in a vicinity are affected resulting in a flat adenoma. These might 
progress to a polyp and are often polyclonal proliferations [92-94]. 
1.1.4. Aberrant crypt foci and adenoma progression 
Experimental animal studies [95] and routine specimens show changes other 
than typical adenomas or hyperplastic polyps with crypt branching and widening 
in the absence of cytological atypia [96, 97]. These hyperplastic foci are clonal 
and show K-ras mutations (possibly relating to Lipkin and Drescher phase 1) 
whereas microadenomas show APC mutations (possibly relating to Lipkin and 
Drescher phase 2) [97]. Flat adenomas lack K-ras mutation whereas polypoid 
adenomas (like the hyperplastic polyps) most commonly have the K·ras mutation 
reflecting possible different pathways of carcinogenesis and tumour progression 
[98-100]. Therefore flat·. depressed- or microadenomas are now well recognized 
and genetically characterized [101, 102]. 
Progression of adenomas seems to follow the initial model of Fearon and 
Vogelstein with mutations of APC, TP53, DCC and K-ras [103]. This is true for 
most sporadic and some FAP cases but does not explain all FAP, non-polyposis, 
villous adenomas to mucinous carcinoma, tumours with low p53 or K-ras 
mutations [98. 104-108]. 
DNA microsatellite instable carcinomas progress through a distinct pathway 
involving mutations of TGF-SRII receptor, GF2R and SAX [80, 109, 110]. 
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The final conversion from adenomas to carcinoma is statistically a very unlikely 
event considering the abundance of adenomas compared to the actual infiltrating 
carcinomas. Multiple changes occur at this stage including metabolic pathways, 
growth factor production with stromal response and angiogenesis, proteolytic 
enzyme activity for invasion, alteration in adhesion molecules, increased 
telomerase activity, alteration to glycoproteins of membranes as well as 
aneuploidy [111-120]. 
1.2. DIAGNOSTIC CRITERIA (AMSTERDAM CRITERIA) 
In 1990 the International Collaborative Group on HNPCC proposed a set of 
diagnostic criteria to set a uniform base for further studies (Amsterdam Criteria I) 
[121, 122]. These were initially not universally accepted and did not allow 
extracolonic presentation of carcinomas as an inqlusive criterion. 
A new set of criteria (Amsterdam Criteria II) has been formulated in 1999 to 
accommodate the extracolonic neoplasias [57]. 
These are summarized as follows: 
There should be at least three relatives with an HNPCC-associated cancer and 
include colorectal carcinoma, endometrial carcinoma, small bowel carcinoma. 
carcinoma of the ureter or renal pelvis. 
1. One patient should be a first degree relative of the other two 


















3. At least one tumour should be diagnosed before the age of 50 
4. Familial adenomatous polyposis should be excluded in cases of colorectal 
carcinoma 
5. Tumours should be verified by histopathological examination 
It is noted that not all families fulfilling these criteria have mismatch repair gene 
defects indicating a percentage of families with a1ternative forms of inherited 
predisposition to develop colon carcinoma [123]. 
I n one study of a Korean cohort, the mutation detection rate is hardly affected by 
the change of criteria from ACI to ACII. The reason being the wide selection of 
individuals at risk for genetiC screening [124]. HNPCC families not complying with 
the ACII show extremely low frequency (8% versus 49% of patients fulfilling the 
ACII) of mismatch repair gene defects and microsatellite instability [125]. 
ACII is reliable and shows reproducible and practical results. However, genetiC 
testing is important in patients suggestive of non-polyposis colorectal carcinoma 
falling short the diagnostic criteria [126]. 
1.3. IMMUNOHISTOCHEMICAL STUDIES ON PROTEIN PRODUCTS IN 
TUMOURS 
Expression of gene products is a normal phenomena, and is in particular 
















129]. Normal staining for gene products is increased in the replicating 
compartment of the colonic epithelium, namely in the base of crypts. 
An unpublished study of immunohistochemical staining for gene products MLH1 
and MSH2. performed in our laboratory using patients with colorectal carcinomas 
under the age of 45 years was undertaken. Of the 51 tumours stained, 12 
(23.5%) showed negative staining for MLH1 and 7 (14%) showed negative 
staining for MSH2, therefore suggesting mismatch repair gene defects. In this 
study, all cases of known HNPCC (germline screened) were identified therefore 
proving. as in other studies, immunohistochemical staining for mismatch repair 
genes to be successful and sensitive [130]. 
1.4. GENETIC STUDIES AND GENE PROFILES 
Genes involved in carcinogenesis (cancer genes) are the imbalance of activation 
or inactivation of proto-oncogenes as well as tumour suppressor genes (see 
table 1.1). 
Proto-oncogenes (oncogenes) promote the proliferation of cells resulting in 
uncontrolled growth. These are usually up regulated in neoplasia (over 
expression). In contrast tumour suppressor genes inhibH: uncontrolled growth of 
cells. In neoplasias these are usually silenced by mutation resulting in down 

















Mutation of proto-oncogenes leads to unregulated growth whereas loss of tumour 
suppressor genes result in uncontrolled cell cycling, reduced DNA repair and 
abnormal signaling pathways [7,131-140]. 
Table 1.1: Summary table of genetic alterations involved in colorectal carcinoma. 
The table indicates the gene involved, the rnicrosatellite stability status of the 
particular gene and the alteration (mutation, LOH or methylation) undergone to 
result in a defective gene function. Adapted from [141]. 
I Alteration Gene MSS MSI·L I MSI-H I 
i 
Mutation APC +++ +++ + 
K-ras ' ++ +++ + I 
i I t 
TP53 +++ +++ + 
--.. 
I 
TGFBetaRII + + +++ 
I .IGF2R - - 1+ 
i 
I BAX - I - • ++ i i 
[ Caspase-5 - I - + r-... CDX-2 - - + 
BCL-10 - + I 
I 




LOH I 5p (APC) +++ '++ -
I I 
I 117p (TP53) +++ 
I 
18q (DCC) +++ i 
I Meth~lation + +++ I 
Oncogenes are either activated by mutation (e.g. K-ras) [7, 131] or dysregulation 











change may manifestate in partial abnormality and does relate to an increase risk 
of carcinoma. 
Inactivation of the one allele of tumour suppressor genes is either an inherited or 
acquired mutation. The second allele may be either by mutation or often loss of 
heterozygosity (LOH) as seen in chromosomes 22q, 17q. 14q. 8p and 1p in 
colorectal carcinoma [143-150). 
Five mismatch repair genes in HNPCC are identified showing an autosomal 
dominant transmission and are listed and described in table 1.2 [151]. 
Table 1.2: Characteristics of known HNPCC-associated DNA mismatch repair 
genes [151J. 
I Gene Chromosome Length Exon number I Genomic size 1 
MSH2 2p21 ·2.8kb 16 73kb I 
I 
I 
I MLH1 3p31-p23 2.3kb 19 ! 58-100 
I 
PMS1 2q31-q33 12.8kb ? ? I 
I 
I 
PMS2 7p22 2.6kb 15 16 I 











The function of mismatch repair genes can be summarized as follows: 
Two heterodimeric complexes· do mismatch recognition: MSH2-MSH3 and 
MSH2-MSH6 complexes. MSH3 and MSH6 are interchangeable whereas normal 
functioning MSH2 is mandatory for recognition of insertion-deletion mismatches. 
Once mismatch binding has occurred, the heterodimeric complex proteins MLH1-
PMS2 and MLH1-MLH3 are mobilized with multiple enzymatic action to repair the 
mismatched base pairs. Once again, MLH1 is essential in this complex for 
successful repair. 
Most mutations in all parts of the world are either MLH1 or MSH2: the essential 
proteins in both identification and repair complexes. Hot spots were identified in 
exon 12 in MSH2 and exon 16 in MLH1 [152]. Less common mutations include 
MSH6. PMS1 and PMS2 [153J. 
Mutations in these DNA mismatch repair genes account for only two-thirds 
meeting the AC!! and showing MSI-H [154] and less than 30% in HNPCC 
kindreds not meeting the ACII [125, 155]. Some patients meeting the ACII, 
showing colonic carcinoma and extracolonic cancers do not show mismatch 
. repair gene mutations but TGFbeta-RIl and E-cadherin and no MSI [156, 157]. 
1.5 COLORECTAL CARCINOMA RESEARCH CONSORTIUM (CRCRC) 
In 1999 a consortium was formed using expertise in the Western Cape to study 
























Colorectal surgeons (Prof. Paul Goldberg and Dr. Fayaz Hameed), 
gastrointestinal physicians (Prof. Japie Louw and Dr. Trevor Winter). anatomical 
pathologists (Prof. Pauline Hall, Dr. Hannes Holm and Dr. Jenny Watkins), 
human geneticists (Prof. Raj Ramesar and Rebecca Felix) and research nurses 
(Ursula Algar) all form part of an integrated team to establish the extent of . 
disease in the Western and Northern Cape regions. 
Financial support and epidemiological data is provided by Cancer Association of 
South Africa (CANSA) and partially funded by THRIP. 
HNPCC patients have been identified in these areas, particularity in the Northern 
Cape province, in villages which often are remote and isolated. See figure·1.2 
showing the distribution of MLH1 mutation families. This again results in a small 
genetiC pool with often high prevalence of mutations within these communities. 
These groups of families are in particular of importance for surveillance and 
prevention of advanced carcinomas. 1079 individuals within 294 families are 
identified to be at risk. So far 291 of these were genetically screened for 
mutations. Those with positive results and those not yet tested undergo regularly 
(yearly) colonoscopic surveillance. 
In the year 2000, 156 colonoscopies were done on the yearly visit to the remote 
clinics. 137 of these showed endoscopically normal bowel and 19 showed 















hyperplastic polyp and the other, non-specific inflammation. The remainder (17) 
of these showed 9 adenomatous polyps, 3 hyperplastic polyps and five other 
non-neoplastic pathologies (inflammation, melanosis coli, lymphoid, etc.). 14% 
of mutation positive individuals developed an adenoma. 
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, Department of Human Genetics, UCT 
30· 
Fig 1.2: Distribution of families is shown in this map in the Western and Northern 
Cape along the west coast. The size of the star represents the number of 
individuals with known MLH1 mutation. The Clanwilliam star represents 
approximately 25 individuals as a rough guide (courtesy Prof. R Ramesar, 











Two studies were undertaken in an attempt to understand and characterize 
HNPCC cases in South Africa: 
1. The pathological characteristics of these tumours were evaluated and 
compared to sporadic tumours in South Africa. 
2. COX-2 expression of HNPCC tumours were evaluated compared to 
sporadic adenomas and carcinomas. 
These results will then be compared to other studies around the world 












CHAPTER lWO: INTRODUCTION 
CYCLOOXYGENASE ENZYME (COX-1 and COX-2) 
2.1 STRUCTURE AND FUNCTION 
27 
Two isoenzymes are described which have very similar crystalline structures: 
COX-1 and COX-2. The gene encoding COX-1 is located on chromosome 9 at 
q32-q33.3 whereas COX-2 in chromosome 1 at q25.2-25.3 (158-160]. COX-2 
has a slightly smaller gene intron of 8~b in COX-2 compared to the 22kb in COX-
1. The reason for this is that COX-2 has a single exon in the place of exons 1 
and 2 in COX-1 [160, 161]. COX-1 and COX-2 have a molecular weight of 71 kb, 
a length of 600 amino acids and 63% identical sequencing [158]. 
COX-2 is found on the on the nuclear- and endoplasmic reticulum membrane 
contrasted to COX-1 which is only found attached to the endoplasmic reticulum 
[160, 162]. COX-1 and COX-2 have no transmembrane domain but are an 
integral part of membrane proteins attached with three amphipathic alpha 
helices. 
Cyclooxygenase (COX) is the enzyme catalyzing the initial steps of transforming 
arachnidonic acid (the substrate) via prostaglandin G2 and prostaglandin H2 to 
the prostanoid end products PGD2, PDE2, PGF2, PGI2 and TXA2 [158, 163). 
COX is classified into two isoenzymes: constitutive (COX-1) enzyme expressed 
















expressed by inflammatory stimuli such as lipopolysaccharide, interleukins (1 
and 2) and tumour necrosis factor alpha (TNF) [159, 160, 163~167l Unlike COX-
1, COX-2 expression can be rapidly reduced once stimuli are subside or become 
absent. 
See figure 2.1 for a simplified illustration of the function and metabolism of COX 





















Fig 2.1: Function and metabolism of COX in the metabolism of Arachnidonic 
acid, the break down products and the postulated mechanism of genetic 











Implantation, foetal and placental development 
COX is expressed in the endometrial epithelium, present at implantation 
(mediation with prostaglandins) of the embryo and establishment of the placental 
vasculature [158, 169, 170]. Animal models show multiple female reproductive 
failures in COX-2-deficient mice [171]. Premature labour is also suppressed by 
COX-2 inhibition, particularly if the labour is associated with infection and release 
of cytokines [172]. COX-2 is of importance in fertility (ovulation, implantation! 
decidual change) [171,173-175]. 
Haematological and vascular effects 
Platelet adhesion is mediated by von Willebrand factor binding to specific platelet 
surface receptors. Adenosine diphosphate (ADP) and thromboxane A2 (TXA2) 
are the two most pivotal platelet-activating factors [176]. Inhibition of COX·1 
leads to reduced TXA2 and therefore reduces platelet aggregation and 
vasoconstriction [176, 177]. COX-1 inhibition on platelets is irreversible and the 
effect lasts ClS long as the lifespan of platelets (8-10 days). This mechanism and 
the effect of COX-1 is used in the treatment of coagulative disorders. 
COX-2 has a lesser effect on platelets and is therefore also not used in 













COX enzyme in the central nervous system 
Both eOX-1 and eOX-2 are expressed in the central nervous system: eOX-1 
widely and generally expressed and eOX-2 mainly in the· forebrain cortex, 
hypothalamus, hippocampus and the spinal cord [158, 169, 179-181]. 
Prostaglandins in the brain are mainly PGE2 and PGD2 subtypes. 
Lipopolysaccharides induce release of cytokines and activate eOX-2 in eNS 
endothelial celis. PGE2 affects the temperature sensitive neurons and results in 
fever induction. eOX-2 is also induced in sensory neurons resulting in 
inflammatory pain [158,169,180,182]. 
Microglial cells also express eOX-2 and prostaglandins particularly in the vicinity 
in neuritic plaques (amyloid containing) seen in Alzheimer diseases. This 
resulted in the postulated partial preventative effect of eOX-2 inhibitor therapy 
[158,169,181,183]. 
Gastrointestinal effects 
eOX-1 has a vasodilator effect and therefore enhances mucosal blood flow. 
eOX-1 inhibition therefore results in erosion, ulceration and the complications 
such as anaemia, perforation and malabsorbtion [158, 169, 177]. This is not the 
only mechanism involved resulting in mucosal damage. Prostaglandins are 
essential in gastric mucosal regeneration and if suppressed result in suppressed 
epithelial regeneration and repair [184]. 
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COX-2 is induced in the gastrointestinal tract following inflammatory stimuli such 
as infection or idiopathic inflammatory bowel disease. Therefore COX-2 inhibition 
worsens healing and aggravates acute idiopathic inflammatory bowel. disease in 
general (184, 185]. 
Renal effects 
COX-1 induction produces PGI2, PGE2 and PGD2 resulting in reduced vascular 
resistance through dilatation of renal vessels and increased organ perfusion. 
Blood is shunted from the renal cortex to the juxtamedLiliary region (169, 186, 
187]. 
COX-2 is associated with renal salt excretion and upregLilation of COX-2 in the 
maculae densa of the juxtaglomerular apparatus and adjacent epithelial cells 
[188, 189]. This is illustrated by sodium retention, generalized oedema and 
increased in blood pressure when inhibiting COX-2 [187, 190]. 
2.2 ROLE IN INFLAMMATION 
The discovery of COX-2 and the initial suggestion that the enzyme is only 
expressed in acute and chronic inflammation raised the possibility of selective 
treatment without side effects of NSAID such as gastriC erosion and renal toxicity 
[191, 192]. This prompted development and production of highly selective COX-



















(over 17 million) take NSAlDs for different types of arthritis of which osteoa'rthritis 
is the most common [193]. 
Many animal models shoW the over expression of COX-2 in acute and chronic 
inflammation [194, 195]. Injecting cotton oil resulting in foreign body reaction and 
chronic inflammation simulates pannus formation and inflammation similar to that 
seen in rheumatoid arthritis [196]. An initial peak in PGE2 at two hours 
corresponds with the affect of acute inflammation in a pleurisy induced animal 
model [196). This proves the role of COX-2 expression in acute inflammation. 
Multiple studies show that COX-2 has a protective role in the gastrointestinal 
tract including those showing increased expression of COX-2 at the edge of 
gastric ulcers and delayed healing of ulcers when treated with COX-2 inhibitors 
[197-199]. 
2.3 ROLE OF COX-2 IN CARCINOGENESIS 
The ability to potentially treat or prevent neoplasia with COX-2 inrlibitors led to 
the investigation of multiple neoplasms and their expression of COX-2. 
Carcinogenesis is a multistep process of long-term accumulation of genetic and 
epigenetic alterations eventually resulting visible changes in the form a 
neoplasia. Understanding these steps will help in the design of targeted therapy 
with strategies for prevention and/or treatment. Epidemiological and experimental 















prostaglandins. COX-2 is often over expressed in many neoplasia and therefore 
is of particular interest for chemoprevention [200]. It is not fully 'understood how 
COX inhibiters prevent carcinoma but some mechanism can be explained, at 
least partially. COX-2 is an important mediator of angiogenesis and tumour 
growth expressed in tumour endothelial cells, immune cells, and stromal 
fibroblast TXA2, PGE2 and PGI2 all result in endothelial growth and 
proliferation, promotion of vascular sprouting, migration and tube formation: 
enhanced endothelial cell survival via bct-2 expression and Akt signaling [201], 
induction of metalloproteinases, activation of epidermal growth factor receptor 
mediated angiogenesis and suppression of interleukin-12 production. COX-2 
inhibitors are shown to suppress angiogenesis [202, 203]. 
COX-2 and gastrointestinal neoplasia 
Normal intestinal mucosa has no expression of COX-2 contrasted to sporadic 
colorectal carcinoma which expresses COX-2 at a high rate [158, 166. 204). 
Gastric adenocarcinoma [157, 182) and oesophageal squamous cell carcinoma 
[212, 213] show increase COX-2 expression and in the case of gastriC carcinoma 
correlates with lymphatic invasion and lymph node metastases. 
COX-2 in oral, laryngeal and lung carcinoma 
Squamous cell carcinomas of the head and neck region show over expression of 














prevented by NSAIDs in animal models [:205]. It is also suggested that radio 
resistant laryngeal squamous cell carcinomas show increased expression of 
COX-2 with a potential benefit of inhibitory therapy [206]. 
COX-2 is also over expressed in lung carcinoma, particularly squamous cell and 
adenocarcinoma with a very low expression in small cell carcinoma. Expression 
also correlates with the degree of differentiation in adenocarcinomas with low 
levels of expression in poorly differentiated adenocarcinomas. Atypical alveolar 
and hyperplastic bronchial epithelium does also show increased expression 
suggesting a neoplastic potential [207, 208]. 
COX-2 expression in breast carcinoma 
COX-2 expression is associated with an aggressive phenotype in ductal 
carcinoma in situ [209]. COX-2 inhibitors are promising but under investigated as 
a potential chemotherapy [210]. 
COX-2 and urogenital neoplasia 
COX-2 is over expressed only in poorly differentiated endometrial carcinomas 
. and known be expressed in ovarian neoplasia [211, 212]. In a study done in our 
department COX-2 expression was evaluated on normal, HPV, CIN I, " and III 
and infiltrating squamous cell carcinoma of the uterine cervix. The results 
indicated no expression in the ectocervix of normal cervix biopsies. All cases of 














expression in CIN I, 1\ and squamous cell carcinoma. Infection by two types of 
HPV correlated with the highest expression of COX-2 [213] ... Some COX-2 
inhibitors have an inhibitory effect on cancer cell proliferation in cell lines of 












MORPHOLOGY STUDY OF COLORECTAL CARCINOMA 
3.1 AIM 
37 
1. The purpose of this section of this study was to blindly evaluate a range of 
the pathological features (intratumoral lymphocytes, stromal lymphocytes, 
lymphoid aggregates, type of necrosis, percentage intra- and extracellular 
mucin and tumour grade) and where possible grade them in histological 
sections of HNPCC tumours. 
2. To compare these findings with genetic germline testing for specific 
mutations and determine whether pathological features per se are 
characteristic of HNPCC colonic carcinomas or not 
3. To determine which pathological features are useful in predicting the 
likeliness of a colorectal carcinoma being an HNPCC lesion. 
Proposal 
If a tumour is suspected to be of HNPCC origin on the basis of pathology, 
tumours could be immunohistochemically stained (MLH1, MSH2) and tumour 
tissue and blood could be genetically tested. New cases and families at risk 
could be identified with this approach and this could lead to regular screening 












3.2 MATERIALS AND METHODS 
Materials 
Blocks and slides were retrieved form the archives of Groote Schuur Hospital, 
division of Anatomical Pathology, National Health Laboratory Service (NHLS). 
Three groups of patients with CRC were included: 
Group 1: Sporadic c%recta/ carcinoma (Sporadic eRG) 
Sixty-five (65) most recent (2001 and 2002). consecutive cases of left sided 
colorectal carcinomas in patients older than 65 years were selected. This was 
done to minimize the possibility of including· cases of inherited cancer 
syndromes. Cases with family history of colorectal carcinoma, prior malignancies, 
histories of previous malignancies or where tissue blocks were not found in the 
archives were excluded. Seven cases were excluded from this study for the 
above-mentioned reasons and the remaining of 58 cases were studied. 
Group 2: Early onset c%rectal carcinoma (less than 45 years of age) 
Ninety three (93) cases of colorectal carcinoma in patients presenting at less 
than 45 years of age were selected over a period of eight years (1993-2001) 
[130]. These cases were diagnosed clinically and confirmed histologically. Cases 
of known MLH1 and MSH2 mutations, known and tested by the division of 
human genetics at UCT, were excluded from this group. This group of cases is 
the same used in a study on MLH1 and MSH2 immunohistochemical staining in 
















Group 3: Genetically proven HNPCC 
This group consisted of thirty (30) cases of known HNPCC carcinomas proven by 
genetic testing for mismatch repair gene (MLH1 and MSH2) germline mutations 
by the division of human genetics, UCT. 
Cases of known FAP, hyperplastic polyposis, juvenile polyposis and colorectal 
neoplasias other than adenocarcinomas were excluded (group 3). 
Methods 
The slides and paraffin blocks were retrieved from the archives. The sections 
were recut if not available or technically sub-optimal, stained with H&E, and 
coded. 
All sections for each cases were evaluated and graded on the following features: 
1. intratumorallymphocytes (tumour infiltrating lymphocytes) 
(Fig. 3.1 and 3.2) 
2. stromal lymphocytes (Fig. 3.3 and 3.4) 
3. lymphoid aggregates (Crohn-like inflammation) (Fig. 3. and 3.4) 
r 4. "dirty" necrosis (Fig 3.5) 
5. % mucin per surface tumour evaluated (intra- and extracellular mucin) 
(Fig. 3.6 to 3.8) 















The figures following under the headings of pathological features assessed are 
representative of the typical morphology seen in these cases and illustrate the 
pathology range encountered (Fig. 3.1 to 3.10). 
See appendix 1 for raw data (table 1) for pathological evaluation. 
1. Intratumoral lymphocytes 
I ntratumoral lymphocytes were scored as present (positive) or absent (negative). 
A positive result WOLlld be tumours where lymphocytes are diffusely present in 
the neoplastic epithelium ("peppered epithelium") and within normal limits (less 
than 20 intraepithelial lymphocytes per 100 epithelial cells) in the non-neoplastic 
epithelium away from the tumour. Small foci of intratumoral lymphocytes often in 
the vicinity of lymphoid follicles, epithelial ulceration or associated necrosis were 
considered negative. Lymphocytes were identified by their typical morphology, 













Fig 3.1: Medium power view of multiple intratumoral lymphocytes in neoplastic 
epithelium (positive result). 
Fig 3.2: High power view of lymphocyte within a colon cancer, some of which 











2. Stromal lymphocytes 
This feature was scored either positive when stromal lymphocytes were present 
in a dense peritumoral sheet or negative when moderate or sparse stromal 
lymphocytic infiltration was seen [53]. See figures 3.3 and 3.4 below. 
Fig 3.3: Medium power view of a reactive lymphoid aggregate with germinal 
center formation (red arrow) in the vicinity of an infiltrating adenocarcinoma (blue 











3. Lymphoid aggregates 
A Crohn-like inflammatory pattern was looked for and was considered positive if 
more than one deep lymphoid aggregate per ten high power fields were apparent 
or negative when less than one lymphoid aggregate per ten high power field was 
present. See 'figure 3.4 showing three lymphoid aggregates in one field. 
Fig 3.4: Deep lymphoid aggregates (red arrow) and dense stromal lymphocytic 
inflammation (blue arrow) in the vicinity of infiltrating tumour and into mesenteric 














Tumour necrosis resulting in areas of cellular tumour debris (so-called "dirty" 
necrosis) was scored positive. Coagulative necrosis and infarcted bowel as well 
as surface epithelium ulceration and necrosis were considered negative. 
Fig 3.5: Neoplastic epithelium with large areas of "dirty" necrosis (arrows). 











5. Percentage of mucin 
On evaluating intra- and extracellular mucin the tumours were grouped into five 
categories depending of the amount of mucin present: 
1. 0% (Fig. 3.6) 
2. < 25% (Fig. 3.7) 
3. 25-50% 
4. 50-75% 
5. > 75% (Fig. 3.8). 
This was estimated by the presence of intra- and extracellular mucin expressed 
in percentage of surface area of tumour examined (amount of mucin production 
expressed in a percentage of surface area evaluated) [53]. 
Fig 3.6: Solid type eRe, poorly differentiated adenocarcinoma with 0% mucin in 
the tumour. 












Fig 3.7: Well-differentiated GRG, non-mucinous adenocarcinoma (mucin 
expression < 25%) 
• -
• • 



























6. Grading (differentiation) 
A four-tiered grading system of the WHO [151] was used. The percentage of the 
tumour showing formation of gland-like structures was evaluated: 
Grade I: well differentiated (more than 95%) (Fig 3.9) 
Grade II: moderately differentiated (50-95%) 
Grade III: poorly differentiated (5-50%) 
Grade IV: undifferentiated carcinomas (less than 5%) (Fig 3.10) 
In the conventional three-tiered grading system well, moderate and poorly 
differentiated grades are used. Grade I and II of the WHO system correlate with 
well- and moderately differentiated tumour grades in the three-tiered system. 
Both the grades III and IV of the WHO grading system correlate with poorly 













Fig 3.9: Well differentiated adenocarcinoma (WHO grade I and well-differentiated 
in three-tiered system) 
Fig 3.10: Poorly differentiated colorectal adenocarcinoma (WHO grade IV and 














See appendix 1, raw data table 1. 
1. Intratumoral lymphocytes 
Most of the HNPCC tumours contain intratumoral lymphocytes. This feature on 
its own identified 70% of HNPCC. 22% of sporadic CRC show this feature while· 
only 15% of CRC in patients less than· 45 years of age show intratumoral 
lymphocytes. See figure 3.1 below. 
Table 3.1: Percentage intratumorallymphocytes 
Group % intratumoral lymphs i 
Sporadic CRC 22% 
CRC less than 45 years 15% 
HNPCC 70% 
2. Stromal lymphocytes 
90% of HNPCC cases show stromal lymphocytes. However. a very high 
percentage (65%) of sporadic CRC and tumours in the under 45-year-old age 
group (78%) show this pathological feature. This is therefore a sensitive but less 











Table 3.2: Stromal lymphocytes in CRC 
Group % stromal lymphs i 
Sporadic CRC 65% 
CRC less than 45 years 78% 
HNPCC 90% 
3. Lymphoid aggregates 
Lymphoid aggregates in the stroma surrounding infiltrating carcinoma are a 
common finding in all carcinomas but are slightly more prevalent in HNPCC (73% 
contrasted to 53% in sporadic CRC. See table 3.3 below. 
Table 3.3: Lymphoid aggregates in CRC 
Group Lymphoid aggregates 
Sporadic CRC 53% 




'Dirty' necrosis is a common histological feature in CRC. 50% of HNPCC cases 
show this feature. Necrosis is more frequent in sporadic carcinomas (62%) and 













Table 3.4: Percentage 'dirty' necrosis in CRC 
Group % necrosis 
Sporadic CRC 62% 
CRC less than 45 years 76% 
HNPCC 50% 
5. Mucin percentage 
The amount of mucin production is of no discriminating use in identifying HNPCC 
tumours (30% mucinous) compared to those of sporadic CRC (26%) or early 
onset CRC (30%). See summary tables 3.5 to 3.10 below. 
Table 3.5: Percentage cases showing 0% mucin in CRC 
Group 0% mucin 
Sporadic CRC 6% 
CRC less than 45 years 17% 
HNPCC 12% 
Table 3.6: Percentage cases showing less than 25% mucin in CRe 
Group less than 25% mucin 
Sporadic CRC 38% 












Table 3.7: Percentage cases showing 25-50% mucin in eRe 
Group 25-50% mucin 
Sporadic CRC 30% 
CRC less than 45 years 12% 
. 
HNPCC 31% 
Table 3.8: Percentage cases showing 50-75% mucin in eRe 
Group 75% mucin 
Sporadic CRC 12% 
CRC less than 45 years 7% 
HNPCC 11% 
Table 3.9: Percentage cases showing more than 75% mucin in eRC 
Group More than 75% mucin 
Sporadic CRC 14% 












Table 3.10: Summary table showing conventional percentage non~mucinous 
carcinomas (less than 50% mucin) and mucinous adenocarcinoma (more than 
50% mucin). 
Group % Non-mucinous % Mucinous 
I 
Sporadic eRe 74% 26% 
eRe less than 45 years 70% 30% 
HNPee 70% 30% 
7. Differentiation 
T.he four tiered system (WHO) initially used was later (see appendix 3, raw data 
table1) consolidated to a three~tiered grading system, since no statistical 
differences were noted in either grading systems. Grading is not a useful 
discriminating histological factor in identifying HNPCC carcinomas and show a 
very similar distribution of numbers in all groups of tumours. See tables 3.1.1 to 
3.15 below. 
Table 3.11: Percentage cases showing grade I differentiation 
Group Grade I I 
Sporadic eRe 17% 
I 












Table 3.12: Percentage cases showing grade II differentiation 
Group Grade II 
Sporadic CRC 66% 
CRC less than 45 years 54% 
HNPCC 50% 
Table 3.13: Percentage cases showing grade III differentiation 
I Group Grade III 
Sporadic CRC 13% 
CRC less than 45 years 33% 
HNPCC 25% 
Table 3.14: Percentage cases showing grade IV aifferentiation 
Group Grade IV 
Sporadic CRC 4% 
i 












Table 3.15: Summary table showing percentage cases in the conventional 
classification based on a three-tiered system. 
Group Well differentiated 
Moderately Poorly 
differentiated differentiated 
Sporadic CRC 17% 66% 17% 
CRC less than 45 years 13% 54% 33% 
HNPCC 25% 50% 25% 
3.4 DISCUSSION 
In this study it is shown that some histopathological features are useful in 
prompting further investigation when considering HNPCC. Documentation of 
detailed histopathological findings in the surgical report of resected CRC is 
warranted and enables us, together with the clinical history and presentation, to 
decide on further immunohistochemical and molecular testing. 
The most useful pathological findings in suggesting an HNPCC are: 
Intratumoral.lymphocytes (70%) as well as lymphoid aggregates (73%), but on 
their own they are not specific histological indicators for HNPCC. The presence 
of intratumoral lymphocyte infiltration is the most suggestive histological indicator 
of HNPCC of all the histological markers. Stromal lymphocytes are a more 
sensitive marker (present in 90% in HNPCC) but less specific since these 
findings are present in 65% of sporadic carcinomas and in 78% of the under 45 
year old group. 'Dirty' necrosis is a more typical feature for sporadic carcinomas 











study [53). However, half of the HNPCC cases also show this feature, which 
makes it a less useful discriminating histological feature. This is in contrast to a 
previous study where 'dirty' necrosis was much less common in HNPCC [53]. 
The categorization of mucinous or non-mucinous tumours is of no discriminatory 
value in identifying HNPCC versus non-HNPCC carcinomas in this study. This is 
in contrast to multiple previously published studies where mucinous tumours 
were more numerous in HNPCC [53, 215]. The reason for this might be the high 
prevalence of MLH1 mutation and less common MSH2 in our South African 
population group. 
The least helpful feature in identifying HNPCC carcinomas was the histological 
grading of tumour; the grading of the tumour (whether three- or four-tiered) was 
of no distinguishing value in this stud  aimed at distinguishing HNPCC tumours 
















Normal intestinal mucosa has no expression of COX-2 contrasted to sporadic 
colorectal carcinoma which expresses a high rate [158, 166; 204] .. In familial 
adenomatous polyposis (F AP) numbers and size of adenomas are reduced in 
patients on NSAID treatment [158, 165, 166, 204, 216]. In clinical practice this 
has led to the use of NSAIDs in patients with known FAP in preventative therapy 
before polyps develop and in patients with polyps preventing progression to 
carcinoma. It has also been proven that colon cancer cells with high invasive 
potential have a susceptible of apoptosis by means of COX-2 inhibitors [217]. In 
contrast to sporadic tumours, expression of COX-2 in HNPCC is reduced [218, 
219]. COX-2 expression is in some studies regarded as an indicator to poor 
outcome since more advanced tumours often show higher levels of COX-2 
expression [220]. However, this is still controversial since other studies did not 
show such a correlation [221]. Chronic inflammatory conditions such as 
ulcerative colitis and Crohn's disease predispose to development of cotorectal 
carcinoma. It is assumed, and supported by rodent models, that chronic 
inflammation with bacterial colonization, prostaglandin and interleukins 
production which leads to dysplasia and malignancy [222-224]. 
Normal colonic mucosa does not express COX-2 in contrast to sporadic and FAP 
colorectal carcinomas where over expression is marked. It is important to note 















and some fibroblastic cells may express COX-2 and this may lead to 
misinterpretation. Positive staining is interpreted as tumour cells showing 
cytoplasmic staining often with perinuclear distribution [158, 166]. 
4.1 AIM 
1. To evaluate COX-2 expression in colonic adenomas and carcinomas in South 
African patients with genetically proven HNPCC. 
2. To compare COX-2 expression in HNPCC cases with that in sporadic CRC. 
Hypothesis 
HNPCC will express COX-2 (as do sporadic CRC) and consequently COX-2 
inhibitor therapy will be warranted. 
4.2 MATERIAL AND METHODS 
Coded sections of formalin fixed, paraffin embedded, archived tissue from 
patients with known hMLH1 or hMSH2 mutations (6 polyps and 17 carcinomas) 
and consecutive sporadic tumours (5 polyps and 39 carcinomas), received during 
the year of the study (2001). where tissue blocks were available were 













Expression of COX-2 in the tumours was scored on intensity where: 
o = staining, 
1 = weak staining, 
2 = intermediate staining and 
3 = intense dark staining. 
Distribution was scored where: 
o = no staining, 
1 = very focal staining, 
2 = moderate staining and 
3 = diffusely positive staining. 
59 
The adjacent normal epithelium was evaluated and compared. This was then 
expressed in a combined score (intenSity + distribution) and scored out of 
maximum score of 6. 
A second pathologist did a random audit looking at a number of slides scoring 



















1 micrometer sections were cut onto APES-coated slides and heat-fixed overnight 
at 60 degree Celsius followed by dewaxing. Endogenous peroxidase reactivity 
was blocked by treating slides with a 1 % H20 2 in water solution' for 15 minutes. 
Antigen retrieval was performed by pressure-cooking in citrate buffer for 2 
minutes at full pressure and immediately immersed in water followed by rinsing 
with phosphate buffered saline solution (PBS pH 7.6). Non-specific binding was 
blocked by treating slides with a 5% goat serum solution (DAKO #X0907). 
The sections were incubated with the primary antibody (1 :200 dilution at room 
temperature for 4 hours and washed with PBS buffer followed by incubation with 
DAKO envision labeled polymer, HRP (DAKO #K4001) for 30 minutes at room 
temperature and again washed with PBS buffer. 
Positivity was developed by applying 3.3-diaminobenzidane (DAKO K3466) for 
10 minutes. The slides were then washed in water, immersed in 1 % CUS04 
solution for 5 minutes and washed in water again. 
The slides were then counterstained with haematoxylin stain and blued in Scott's 














The normal colonic epithelium does not show any COX-2 expression (See fig.4.1 
below). 1/6 adenomas (17%) of HNPCC showed positive expression and 7/17 
carcinomas (41 %) expressed COX-2 (See figures 4.3,4.4 and table 4.1). 
Fig 4.1: COX-2 expression in an HNPCC case with no staining of normal colonic 












In sporadic carcinomas 3/5 adenomas (60%) and 26/39 (67%) of carcinomas 
express COX-2 (see fig. 4.2 below). 
Fig 4.2: Strong COX-2 expression in sporadic colorectal carcinoma 
Only sporadic carcinomas showed high levels of expression (4/6 and 5/6)(see 
figure 4.2) in contrast to HNPCC cases, which showed highest expression with a 
combined (distribution and intensity) score of 3/6 (only three cases). 











Fig 4.3: Weak and focal COX-2 expression in an HNPCC colorectal carcinoma 











Table 4.1: Intensity and distribution of COX-2 staining in HNPCC and sporadic 





Number of H N pee 




0 2 3 4 5 6 
Intensity and distribution (0-6) 
4.4 DISCUSSION 
In this study, known HI\lPCC cases showed less expression of COX-2 than in 
sporadic CRC. Adenomatous polyps show similar results compared to colorectal 
carcinomas but too few cases were evaluated to have any statistical significance. 
Adenomas showed generally less expression and therefore COX-2 expression 
might be a late manifestation in progression to invasive malignancy. This is also 
very suggestive of different pathways of carcinogenesis in HNPCC compared to 










In summary the following could be extrapolated from the above results: 
1. Adenomas 
65 
Only 17% of HNPC adenomas express COX-2 in contrast to 60% of sporadic 
adenomas. 
2. Carcinomas 
Only 41 % oJ HNPCC express COX-2 in contrast to 67% of sporadic CRC. 
HNPCC and adenomas do not express COX-2 as strongly as sporadic CRC and 
adenomas in this study. 
These results suggest chemoprevention with COX-2 fnhibitors (NSAIDs) may 
have a place only in selected patients with HNPCC. COX-2 inhibitor therapy 
might not be as successful in delaying carcinogenesis and preventing infiltrating 














SUMMARY AND FUTURE DIRECTIONS 
The two studies and described in this thesis gave insight and understanding in 
the pathogenesis, genetics and morphological features of South African HNPCC 
cases. This enables us to construct a profile of these unique cases based on 
epidemiology, genetics, morphology, clinical outcome and therapy -ultimately 
leading to effective management with effective screening, early diagnosis, 
prevention and effective therapy. All these observations will hopefully benefit 
patients and relatives in HNPCC families who are at risk of developing 
carcinomas with associated morbidity and mortality. 
Some, but not all, of the findings in these studies are in keeping with published 
findings of other study groups around the world. 
The morphological study confirmed other studies of the diagnostic usefulness of 
certain histological features. Intratumoral lymphocytes, stromal lymphocytes and 
lymphoid aggregates suggested HNPCC cases (or MSI-H). The presence of 
"dirty" necrosis is a more common histological finding suggesting sporadic rather 
than HNPC carcinomas. 
I n contrast to most other studies, mucinous tumours were not more commonly 
seen in HNPCC in South African patients in this study. Also, the grade of the 















The results of this study will be usefully applied in our daily laboratory practice 
illustrated by the following example: 
A right-sided colectomy for colorectal carcinoma/lesion from a 38-year-old male 
colored patient was submitted for routine histological examination. The histology 
showed occasional adenomas and an infiltrating carcinoma showing marked 
intratumora\ lymphocytes, stromal lymphocytes and lymphoid aggregates. These 
findings were suggestive of MSI-H carcinoma and immunohistochemical studies 
(MLH1, MSH2) for protein products were performed (already tested and proven 
useful in our I HC laboratory [130]). 
Absence of staining sllggested dysfunctional mismatch repair gene. However, 
this could represent either a germline or somatic mutation. Gerrnline testing 
(blood sample) for that specific gene locus (e.g. MLH1) was performed at the 
department of Human Genetics giving a definitive positive result on the germline 
status. In the future this type of investigation could identify new families or family 
members at risk. A preventative and early diagnosis colonoscopy-screening 
program is the adhered too. In future, screening programs for endometrial and 
breast carcinomas are also planned. 
The results of the COX-2 expression by the tumours in this study suggests that 
there may be a place for chemoprevention with NSAIDs in HNPCC cases since 















Side effects (potential adverse effect on the cardiovascular system), it is probably 
worthwhile testing the CRC for COX-2 expression before commencing 
chemoprevention with NSAI Ds [225-227]' 
Future directions 
Future studies in the investigation of HNPCC are of considerable promise; some 
of these studies have been initiated already in selected pilot studies. These 
include mainly molecular analysis of the tumour itself and both the techniques 
and the analysis by microsatellite profiling of tumours and CGH of the genome of 
normal epithelium, adenomas, infiltrating carcinomas and metastasis (please see 
preliminary results on pilot studies in the appendix, raw data, table 3 and figure 
1). Hopefully, such studies will provide insight in the molecular changes 
associated with each stage of carcinogenesis in HNPCC. Once these analyses 
have been completed a correlation with the known mutations, the presence of 
additional mutations and specific oncogenes and whether tumor suppressor 
genes are up- or down regulated will be seen. 
Tissue samples continue to be collected and frozen for future microarray analysis 
(RNA), giving us even more detailed information on exact molecular and genetic 
changes. 
COX-2 expression should be evaluated and compared pre-therapy (at biopsy 














COX-2 inhibitors would be given between the time of original biopsy and formal 
resection (1-2 weeks usually). This will give as a clear indication of the effect of 
therapy on HNPCC cases. 
Chemopreventative therapy probably will be effective if the COX-2 expression is 
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Oral presentation at the National Pathology Congress, Johannesburg 2004 
MORPHOLOGICAL FEATURES OF HEREDITARY NON·POL YPOSIS 
COLORECTAL CARCINOMAS COMPARED TO OTHER EARLY ONSET AND 
SPORADIC COLORECTAL CARCINOMAS. 
H Holm, P de la M Hall, N Allie, R Ramesar.* Divisions of Anatomical Pathology 
and Human Genetics* University NHLS of Cape Town and Groote Schuur 
Hospital 
Background: 
Families with hereditary non-polyposis colorectal carcinoma (HNPCC) are not 
uncommon along the West-Coast of South Africa. These patients present with 
early onset carcinomas mostly colorectal, predominantly in the right colon. They 
may develop tumours of other organs, including uterus, breast, stomach and 
skin. 
Objectives: 
1. To evaluate and compare the microscopic characteristics of three groups of 
colorectal carcinomas (HNPCC, early onset colorectal carcinomas and sporadic 
colorectal carcinomas). 
2. To determine the features most characteristic of the group. 
Methods: 
Coded sections of formalin-fixed paraffin-embedded tissue from patients with 
(1) sporadic colorectal carcinomas (58 cases) 
(2) early onset «45 years) colorectal carcinomas (93 cases) and 













Intratumoral lymphocytes (TL), sromal lymphocytes (SL), lymphoid aggregates in 
the vicinity of the tumour (LA), presence and type of necrosis (Ne), percentage of 
mucin (Mo = 0%, M1 = <25%, M2 = 25-50%, M3 = 50-75%, 4 = >75%) and 
histological grade based on the standard criteria of gland formation (G1 to G4). 
Results: 
I Group TL SL LA Ne MO I M1 M2 M3 1 M4 I G1 : G2 G31G41 
Sporadic 22 65 53 62 6 
1
38 30 12 ! 14 116 58 12 4 1% 
<45 year 15 • 78 50 76 17 141 [12 7 123 13 54 ·32 0 1% 1 
HNPCC 70 90 73 50 12 I 27 i 31 11 I 19 23 47 I 23 0 1% I 
Conclusions: 
lritratumoral lymphocytes and lymphoid aggregates .are fairly sensitive markers 
for HNPCC, the former being more specific than the laUer. Stromal lymphocytes 
are a third, even more sensitive marker for HNPCC, but less specific than the 
other two. The other parameters tested are of no help in the differential diagnosis 
except for presence of necrosis, which is more typical of sporadic and early onset 













Poster presentation at the National Pathology Congress, Bloemfontein 2002 and 
the annual research day at UCT 2003. 
CYCLOOXYGENASE-2 (COX-2) EXPRESSION IN POLYPS AND 
CARCINOMAS OF HEREDITORY NON-POLYPOSIS COLORECTAL 
CARCINOMA (HNPCC) AND SPORADIC COLORECTAL CARCINOMAS. 
H Holm, P de la M Hall, N Allie, R Ramesar* 
Division of Anatomical Pathology and Human Genetics,* Groote Schuur 
Hospital/University of Cape Town. 
Background: 
COX-2 inhibitors are being used as chemoprevention in familial adenomatous 
polyposis. If COX-2 is also expressed in HNPCC there might be a role of COX-2 
inhibitor treatment for patients with known a mismatch repair gene defect - either 
to inhibit progression of tumours or to prevent the onset of carcinogenesis. 
Objectives: 
1. To evaluate COX-2 expression· in colonic adenomas and carcinomas in 
patients with genetically proven HNPCC. 
2. To compare COX-2 expression in HNPCC cases with that in sporadic 
tumours. 
Methods: 
Coded sections of formalin fixed paraffin embedded tissue from patients with 
known hMLH1 or hMSH2 mutations (6 polyps and 12 carcinomas) and sporadic 
tumours (5 polyps and 39 carcinomas) where immunohistochemically stained 
with an antibody to the COX-2 (Santa Cruz). Expression of COX-2 in the 
tumours was scored on both intensity and distribution and compared. to the 
















Normal colonic epithelium does not express COX-2. HNPCC: 1/6(17%) polyps 
and 5/17(41%) carcinomas express COX-2. Sporadic tumours: 3/5(60%) 
polyps and 26/39(67%) carcinomas express COX-2. 
Conclusions: 
COX-2 is generally more expressed in sporadic compared to HNPCC tumours. 
Furthermore COX-2 expression is more often expressed in infiltrating lesions 
compared to the expression in polyps. These results support the theory of 
different pathways in carcinogenesis in colorectal carcinoma. Chemoprevention 













Table 1: An example of a histological scoring data table as used for the study on . 
morphological features of CRC .. 
Stromal Lymph 
Name Number Grading Necrosis % Mucin Intrat L L foil 
! 
1
1978 6022 2 0 >75 0 1 1 
1978 6176 2 0 <25 1 1 1 
1989 6412 2 1 <25 0 1 1 
! 
'1989 6412 2 0 25-50 1 1 1 
1 
1989 14509 2 0 <25 0 1 1 
11989 16342 2 0 <25 0 1 1 
l1991 2089 2 1 <25 1 0 1 
h991 9053 1 1 <25 1 1 1 
1
1992 5740 2 0 <25 1 1 1 
1992 11950 2 1 <25 0 1 0 
1993 6951 1 0 <25 1 1 0 
1993 10500 1 1 25-50 0 0 0 
1993 13457 2 0 <25 0 1 0 
1994 1085 1 0 25-50 1 1 1 
1994 1362 2 0 <25 0 0 0 
i1994 6525 1 0 50-75 0 1 0 
1994 8065 2 0 <25 1 0 0 
1994 8667 0 >75 1 1 0 
1994 9148 2 0 25-50 1 1 1 
1994 13027 3 1 25-50 0 0 1 
1994 13027 3 1 >75 0 1 1 














Table 2: Example of data sheet used for scoring COX-2 staining. Both intensity 
and distribution is scored (0-3). 
Number Year Distribution Intensity Ca/polyp Group 
607 2001 11 1 1 1 
1362 1994 0 0 2 1 
1894 2002 1 3 2 1 
2065 2002 2 3 2 1 
12534 1997 2 1 1 1 
3111 2001 0 0 2 1 
4389 2001 1 2 2 1 
4972 1996 0 0 2 1 
5373 2001 2 1 2 1 
5374 2001 0 0 1 1 
15857 2002 1 1 2 1 
6525 1994 2 2 2 1 
6703 2001 0 0 2 1 
6837 2001 1 1 2 1 
17841 2001 1 1 2 1 
9150 2001 1 1 2 1 
9258 2001 1 1 2 1 
.10113 2001 3 2 2 1 I 
10331 2001 1 2 2 1 
10974 2000 0 0 2 1 
11865 2000 1 1 2 1 
309 1997 1 1 12 2 
791 1996 0 0 2 2 
1615 1994 2 2 2 2 
1662 1987 0 0 2 2 
12213 1994 0 0 1 2 
12977 2002 2 2 2 2 
,3444 2002 1 2 2 2 
3478 1995 1 2 2 2 
4067 1990 0 0 2 !2 
4069 1992 1 2 2 2 
5158 1995 1 1 2 2 
5515 2001 2 3 2 2 
!5987 1994 2 3 2 2 
'6733 1995 2 1 1 2 
7980 1997 0 0 2 2 
8976 1995 1 1 2 2 
'10118 1998 1 2 2 2 
h0253 1999 0 0 2 2 
i365 1992 1 1 2 3 











1951 1990 0 0 1 3 
2960 2001 0 0 1 3 
4648 1996 1 2 2 3 
5237 2001 1 1 1 3 
6412 1989 0 0 2 3 
9053 1995 1 1 1 3 
9054 1995 0 0 2 3 
10182 2000 0 0 2 3 
10356 1998 0 0 2 3 
:10496 2001 1 1 2 3 
11036 2001 0 0 2 3 
12367 1991 1 2 2 3 
12737 1999 0 0 1 3 
13057 1994 2 1 2 3 










Table 3: MSI profile results of a pilot study on ~2 of genetically proven HNPCC cases. MSI- markers used are listed on 
the left column with their loci and gene involved. 
Repeat locus 
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MSOUTHEY PANEL • 
n' 10 
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Overall Score I 511 I 411 I 5/9 I 6/5 I 6/9 I 6/9 I 9/9 I 0/3 I 0/6 I 0/& I 111 I 1/10 
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